Europe
CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.
BioArctic AB announced that the Annual Report for the 2018 fiscal year has been published.
Murepavadin is the lead, pathogen specific, Phase III antibiotic belonging to the OMPTA family and potentially the first drug of a new class of antibiotics against Gram-negative bacteria in more than 50 years
Novartis will use a priority review voucher to expedite review of the treatment that could hit blockbuster status within two years of launching.
This week, a researcher with The Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust published research that showed another mechanism for how colon cancer cells hide from the immune system. They published their work in the Journal of ImmunoTherapy of Cancer.
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab) into familial adenomatous polyposis, a disease of the gastrointestinal tract.
Insilico Biotechnology AG announces the opening of a representation in Singapore to develop its business in the Asia-Pacific (APAC) region and to strengthen support for its growing customer base.
ADOCIA announces its financial results, including revenue and cash position, for the quarter ended March 31st, 2019.
Major framework agreement signed with Life Healthcare Distribution (“LHC”) for the exclusive distribution of HEMOBLAST Bellows in the sizeable and growing Australian market
PRESS RELEASES